Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
Over the Wire Delivery System
INSTRUCTIONS FOR USE
Th e fo llowing l ist i ncludes trademarks o r reg istered trademarks o f Medtro nic i n th e Uni ted States and poss ibly in other
co untries. All o ther trademar ks are the pro perty o f their respecti ve own ers.
End eavor, Medtro n ic, Reso lute Integrity
CAUTION – Fed eral (USA) law restricts this device for sale by or on the order of a physician.
Table of Contents
1 RESOLUTE INTEGRITY™ ZOTAROLIMUS ELUTING CORONARY STENT SYSTEM ..................... 1
1.1 DEV ICE COMPONE NT DESCRIPTION .......................................................................................... 2
1.2 DRUG COMPONENT DESCRIPTION ............................................................................................ 3
1.2.1 Zotarolimus ................................................................................................................... 3
1.2.2 Polymer System Description ............................................................................................ 3
1.2.3 Product Matrix and Zotarolimus Content ............................................................................ 4
2 INDICATIONS ......................................................................................................................... 5
3 CONTRAINDICATIONS............................................................................................................ 5
4 WARNINGS ............................................................................................................................ 5
5 PRECAUTIONS....................................................................................................................... 5
5.1 PRE- AND POST-PROCEDURE ANTIPLATELET REGIMEN.................................................................. 6
5.1.1 Oral Antiplatelet Therapy ................................................................................................. 6
5.2 USE OF MULTIPLE STENTS ..................................................................................................... 7
5.3 USE IN CONJUNCTION WITH OTHER PROCEDURES........................................................................ 7
5.4 BRACHYTHERAPY ................................................................................................................. 7
5.5 USE IN SPECIAL POPULATIONS ................................................................................................ 7
5.5.1 Pregnancy..................................................................................................................... 7
5.5.2 Lactation ....................................................................................................................... 8
5.5.3 Gender ......................................................................................................................... 8
5.5.4 Ethnicity ........................................................................................................................ 8
5.5.5 Pediatric Use ................................................................................................................. 8
5.5.6 Geriatric Use ................................................................................................................. 8
5.5.7 Lesion/Vessel Characteristics........................................................................................... 8
5.6 DRUG INTERACTIONS ............................................................................................................ 8
5.7 MAGNETI C RESONANCE IMAGING (MRI)..................................................................................... 9
5.8 STENT HANDLI NG PRECAUTIONS .............................................................................................. 9
5.9 STENT PLACEMENT PRECAUTIONS ......................................................................................... 10
5.10 STENT/SYSTEM REMOVAL PRECAUTIONS ................................................................................. 10
5.11 POST-P ROCEDURE ............................................................................................................. 11
6 DRUG INFORMATION ........................................................................................................... 11
6.1 MECHA NISMS OF ACTION ..................................................................................................... 11
6.2 METABOLISM..................................................................................................................... 11
6.3 PHARMACOKINETICS OF THE RESOLUTE STE N T ......................................................................... 11
6.4 PHARMACOKINETICS FOLLOWING MUL T I -DOSE INTRAVENOUS ADMINISTRATION OF ZOTAROLIMUS .......... 12
6.5 MUTAGENESIS, CARCINOGENICITY AND REPRODUCTIVE TOXICOLOGY ............................................. 13
6.5.1 Mutagenesis ................................................................................................................ 13
6.5.2 Carcinogenicity ............................................................................................................ 13
6.5.3 Reproductive Toxicology ............................................................................................... 13
6.6 PREGNANCY ..................................................................................................................... 13
6.7 LACTATION ....................................................................................................................... 14
7 OVERVIEW OF CLINICAL TRIALS.......................................................................................... 14
8 ADVERSE EVENTS ............................................................................................................... 19
8.1 OBSERVED ADVERSE EVENTS ............................................................................................... 19
8.2 POTENTIAL ADVERSE EVENTS ............................................................................................... 21
8.2.1 Potential Adverse Events Related to Zotarolimus .............................................................. 21
8.2.2 Potential Adverse Events Related to BioLinx polymer ........................................................ 21
8.2.3 Potential Risks Associated with Percutaneo us Coronary Diagnostic and Treatment Procedures21
i
9
CLINICAL STUDIES .............................................................................................................. 22
9.1 RESULTS OF THE RESOLUTE US TRIAL ................................................................................. 22
9.2 RESULTS OF THE RESOLUTE AC CLINICAL TRIAL..................................................................... 49
9.3 RESULTS OF THE RESOLUTE INTERNATIONAL STUDY ................................................................ 55
9.4 RESULTS OF THE RESOLUTE FIM CLINICAL TRIAL.................................................................... 57
9.5 RESULTS OF THE RESOLUTE JAPAN CLINICAL TRIAL................................................................. 62
9.6 RESULTS OF THE RESOLUTE INTEGRITY US POST MARKET STUDY ........................................... 67
9.7 SUBJECTS WITH DIABETES MELLITUS IN THE RESOLUTE POOLED ANALYSIS...................................... 71
9.7.1 Subjects with Diabetes Mellitus in the RESOLUTE 38 mm Length Stent Sub-study ................ 74
9.8 SUBJECTS WITH CHRONIC TOTAL OCCLUSION ........................................................................... 75
9.9 POOLED RESULTS OF THE GLOBAL RESOLUTE CLINICAL TRIAL PROGRAM (RESOLUTE FIM,
RESOLUTE US, RES O LU TE AC, RES OL UTE INT, RES O LU TE JAPAN) .................................... 79
9.9.1 Gender Analysis f rom the RESOLUTE Pooled On-label Dataset.......................................... 82
9.9.2 Subset Analyses from the Resolute Pooled Dataset........................................................... 86
10 PATIENT SELECTION AND TREATMENT ............................................................................... 88
11 PATIENT COUNSELING INFORMATION ................................................................................. 89
12 HOW SUPPLIED ................................................................................................................... 89
13 DIRECTIONS FOR USE ......................................................................................................... 89
13.1 ACCESS TO PACKAGE HOLDING STE R I LE STE NT DELIVERY SYS TEM ............................................... 89
13.2 INSPECTION PRIOR TO USE................................................................................................... 89
13.3 MATERIALS REQUIRE D......................................................................................................... 90
13.4 PREPARATION PRE CAUTION .................................................................................................. 90
13.4.1 Guidewire Lumen Flush................................................................................................. 90
13.4.2 Delivery System Preparation .......................................................................................... 90
13.5 DELIVERY PROCEDURE........................................................................................................ 91
13.6 DEPLOYMENT PROCEDURE ................................................................................................... 91
13.7 REMOVAL PROCEDURES ...................................................................................................... 92
13.8 IN-VITRO INFORMATION: ....................................................................................................... 92
13.9 FURTHER DILATATION OF STE N TE D SEGMENT ........................................................................... 92
14 REUSE PRECAUTION STATEMENT ....................................................................................... 93
DISCLAIMER OF WARRANTY ........................................................................................................... 94
ii
THE COMPONENTS OF THE RESOLUTE INTEGRITY ZOTAROLIMUS-ELUTING CORONARY STENT
SYSTEM ARE STERILE.
1 RESOLUTE INTEGRITY™ ZOTAROLIMUS ELUTING CORONARY STENT SYSTEM
The Med tronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System (Resolute Integrity
System) is a device/drug combination product comprised of the following device components: the
Integrity coronary stent and MicroTrac™ delivery systems and a drug component (a formulation of
zotarolimus in a polymer coating). The characteristics of the Resolute Integrity System are described in
Table 1-1.
Table 1-1: Device Component Description and Nominal Dimensions
Resolute Integrity Zotarolimus-Eluting Coronary Stent System
Component
Small Vessel Medium/Large Vessel
Available Stent Diameters (mm): 2.25, 2.5, 2.75 3.0, 3.5, 4.0
Available Stent Lengths
Unexpanded (mm):
Stent Material & Geometry:
Drug Component: A coating of polymers loaded with zotarolimus in a formulation applied to the entire surface
Delivery System Working Length: 140 cm
Delivery System Luer Adapter Ports: Two-arm luer (side arm for access to balloon inflation/deflation lumen. Straight arm is
Stent Delivery Balloon:
8, 12, 14, 18, 22, 26, 30 9, 12, 15, 18, 22, 26, 30, 34, 38
A cobalt-based alloy conforming to ASTM
F562 and ISO 5832-6:1997 with 1.0 mm
length elements, 7.5 alternating crowns and
0.0035” strut thickness; the stent utilizes a
single helix fusion pattern. The coronary
stent is formed from a single wire bent into a
continuous sinusoid pattern and then laser
fused back onto itself. The stents are
provided in multiple lengths and diameters.
of the stent at a dose of approximately 1.6 μg/m m
drug content of 380 μg on the largest st ent (4.0 mm x 38 m m).
continuous with shaft inner lumen). Designed for guidewire less than or equal to 0.36 mm
(0.014 inch).
Single-layer Pebax balloon, wrapped over an inner member tubing with 2 radiopaque
marker bands to locate the stent edges.
Over the Wire Delivery System
A cobalt-based alloy conforming to ASTM
F562 and ISO 5832-6:1997 with 0.9 mm
length elements, 9.5 alternating crowns
and 0.0035” strut thickness; utilizes a
helical u-joint fusion pattern. The coronary
stent is formed from a single wire bent into
a continuous sinusoid pattern and then
laser fused back onto itself. The stents are
provided in multiple lengths and diameters.
2
which results in a maximum nominal
Balloon Inflation Pressure: Nominal Pressure: 9 ATM (912 kPa)
Rated Burst Pressure: 16 ATM (1621 kPa) for 2.25 - 3.5 mm diameters
15 ATM (1520 kPa) for 4.0 mm diameter
Minimum Guide Catheter Inner
Diameter:
Catheter Shaft Outer Diameter: Proximal OD: 3.4 F (1.1 mm, 0.044 inch)
≥ 5 F (1.42 mm, 0.056 inch)
Distal Section OD: 2.7 F (0.91 mm, 0. 036 inch)
1
1.1 Device Component Description
The Med tronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (Resolute Integrity
System) consists of a balloon-expandable intracoronary drug-eluting stent pre-mounted on the
MicroTrac Over the Wire (OTW) stent delivery system. The Resolute Integrity stent is manufactured
f rom a cobalt alloy and is formed from a single wire bent into a continuous sinusoid pattern and then
laser f used back onto itself. The stents are available in multiple lengths and diameters. The delivery
system has two radiopaque markers to aid in the placement of the stent during fluoroscopy and is
co mpatible with 0.014 inch (0.36 mm) guidewires. The MicroTrac OTW delivery system (Figure 1-1) has
an ef f ective length of 140 cm.
Figure 1-1: MicroTrac OTW Delivery System (with Stent)
The stent is crimped on various size delivery catheter balloons, which are sized from 2.25 to 4.0 mm.
The Resolute Integrity available stent sizes are listed in Table 1-2.
Table 1-2: Resolute Integrity Stent Sizes
Diameter
(mm)
2.25
2.5
2.75
3.0 ---
3.5 --- 9 9 --- 9 9 9 9 9 9 9
4.0 --- 9 9 --- 9 9 9 9 9 9 9
Note: “---“ indicates sizes not offered; “9” indicates s izes off ered.
8 9 12 14 15 18 22 26 30 34 38
9
9
9
9 9
---
9 9
---
9 9
---
9 9
Stent Length (mm)
9 9 9 9
---
9 9 9 9
---
9 9 9 9
---
9 9 9 9 9 9 9
---
--- ---
--- ---
--- ---
2
1.2 Drug Component Description
The drug coating of the Resolute Integrity System consists of the drug zotarolimus (the active
ingredient) and BioLinx
®
polymer system (the inactive ingredient).
1.2.1 Zotarolimus
The active pharmaceutical ingredient utilized in the Resolute Integrity System is zotarolimus. It is a
tetrazole-containing macrocyclic immunosuppressant.
The Chemical name of zotarolimus is:
[3S-3R*[S*(1R*,3S*,4R*)],6S*,7E,9S*,10S*,12S*,14R*,15E,17E,19E,21R*, 23R*, 26S*,27S*,34aR*]]9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[2-[3-methoxy-4(1H-tetrazol-1-yl)cyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy3H-pyrid o[2,1-c] [1,4] oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone.
The chemical structure of zotarolimus is shown in Figure 1-2:
NN
N
N
MeO
N
O
Figure 1-2: Zotarolimus Chemical Structure
Zotarolimus has extremely low water solubility and is a lipophilic compound that is freely soluble in
Propylene glycol, Acetone, Toluene, Acetonitrile, Ethanol, Benzyl alcohol and DMSO. The molecular
formula of zotarolimus is C
52H79N5O12
and its molecular weight is 966.2.
Zotarolimus does not have any ionizable group(s) in the physiological pH range; therefore, its solubility
is exp ected to be unaltered in this range.
1.2.2 Polymer System Description
The Resolute Integrity stent is comprised of a bare metal stent with a Parylene C primer coat and a
co ating that consists of a blend of the drug zotarolimus and the BioLinx polymer system. BioLinx is a
blend of the Medtronic proprietary components C10 and C19, and PVP (polyvinyl pyrrolidone). The
structural formula of the BioLinx polymer subunits are shown in Figure 1-3:
OO OH
O
O
MeO
OHO
OMe
O
C10 Polymer C19 Polymer PVP Polymer
Figure 1-3: Chemical Structure of the BioLinx Polymer Subunits
3
1.2.3 Product Matrix and Zotarolimus Content
(μg)
Table 1-3: Resolute Integrity Zotarolimus-Eluting Coronary Stent System Product
Matrix and Nominal Zotarolimus Doses
Product Number
OTW
RSINT22508W 2.25 8 59
RSINT25008W 2.5 8 59
RSINT27508W 2.75 8 59
RSINT30009W 3.0 9 90
RSINT35009W 3.5 9 90
RSINT40009W 4.0 9 90
RSINT22512W 2.25 12 85
RSINT25012W 2.5 12 85
RSINT27512W 2.75 12 85
RSINT30012W 3.0 12 120
RSINT35012W 3.5 12 120
RSINT40012W 4.0 12 120
RSINT22514W 2.25 14 102
RSINT25014W 2.5 14 102
RSINT27514W 2.75 14 102
RSINT30015W 3.0 15 150
RSINT35015W 3.5 15 150
RSINT40015W 4.0 15 150
RSINT22518W 2.25 18 128
RSINT25018W 2.5 18 128
RSINT27518W 2.75 18 128
RSINT30018W 3.0 18 180
RSINT35018W 3.5 18 180
RSINT40018W 4.0 18 180
RSINT22522W 2.25 22 153
RSINT25022W 2.5 22 153
RSINT27522W 2.75 22 153
RSINT30022W 3.0 22 220
RSINT35022W 3.5 22 220
RSINT40022W 4.0 22 220
RSINT22526W 2.25 26 188
RSINT25026W 2.5 26 188
RSINT27526W 2.75 26 188
RSINT30026W 3.0 26 260
RSINT35026W 3.5 26 260
RSINT40026W 4.0 26 260
RSINT22530W 2.25 30 213
RSINT25030W 2.5 30 213
RSINT27530W 2.75 30 213
Nominal Expanded
Stent ID (mm)
Nominal Unexpanded
Stent Length (mm)
Nominal Zotarolimus
Content
4
Table 1-3: Resolute Integrity Zotarolimus-Eluting Coronary Stent System Product
(μg)
Matrix and Nominal Zotarolimus Doses
Product Number
OTW
RSINT30030W 3.0 30 300
RSINT35030W 3.5 30 300
RSINT40030W 4.0 30 300
RSINT30034W 3.0 34 340
RSINT35034W 3.5 34 340
RSINT40034W 4.0 34 340
RSINT30038W 3.0 38 380
RSINT35038W 3.5 38 380
RSINT40038W 4.0 38 380
2 INDICATIONS
The Resolute Integrity Zotarolimus-Eluting Coronary Stent System is indicated for improving coronary
luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart
disease due to de nov o lesions of length 35 mm in native coronary arteries with reference vessel
diameters of 2.25 to 4.2 mm. In addition, the Resolute Integrity Zotarolimus-Eluting Coronary Stent
System is indicated for treating de novo chronic total occlusions.
3 CONTRAINDICATIONS
The Resolute Integrity System is contraindicated for use in:
• Patients with known hypersensitivity or allergies to aspirin, heparin, bivalirudin, clopidogrel,
prasug rel, ticagrelor, ticlopidine, drugs such as zotarolimus, tacrolimus, sirolimus, everolimus, or
similar drugs or any other analogue or derivative.
• Patients with a known hypersensitivity to the cobalt-based alloy (cobalt, nickel, chromium, and
molybdenum).
• Patients with a known hypersensitivity to the BioLinx polymer or its individual components (see
details in Section 1.2.2 – Polymer System Description).
Coronary artery stenting is contraindicated for use in:
• Patients in whom anti-platelet and/or anticoagulation therapy is contraindicated.
• Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon
or proper placement of the stent or stent delivery system.
4 WARNINGS
• Please ensure that the inner package has not been opened or d amaged as this would indicate the
sterile barrier has b een breached.
• The use of this product carries the same risks associated with coronary artery stent implantation
procedures which include subacute and late vessel thrombosis, vascular complications, and/or
bleeding events.
• This p ro d uct should not be used in patients who are not likely to comply with the recommended
antiplatelet therapy.
5 PRECAUTIONS
• Only p hysicians who have received adequate training should perform implantation of the stent.
• Subsequent stent restenosis or occlusion may require repeat catheter-based treatments (including
ballo on d ilatation) of the arterial segment containing the stent. The lo ng-term outcome following
repeat catheter-based treatments of previously implanted stents is not well characterized.
• The risks and benefits of stent implantation should be assessed for patients with a history of severe
reactio n to contrast agents.
Nominal Expanded
Stent ID (mm)
Nominal Unexpanded
Stent Length (mm)
Nominal Zotarolimus
Content
5
• Do not expose or wipe the product with organic solvents such as alcohol.
• When drug eluting stents (DES) are used outside the specified Indications for Use, patient
outcomes may differ fro m the results observed in the RESOLUTE pivotal clinical trials.
• Comp ared to use within the specified Indications for Use, the use of DES in patients and lesions
outside of the labeled indications, including more tortuous anatomy, may have an increased risk of
adverse events, including stent thrombosis, stent embolization, MI, or death.
• Care should be taken to control the position of the guide catheter tip during stent delivery,
deployment, and balloon withdrawal. Before withdrawing the stent delivery system, visually confirm
co mplete balloon deflation by fluoroscopy to avoid guiding catheter movement into the vessel and
sub sequent arterial damage.
• Stent thrombosis is a low-frequency event that is frequently associated with myocardial infarction
(MI) o r d eath. Data from the RESOLUTE clinical trials have been prospectively evaluated and
adjudicated using the d efinition developed by the Academic Research Consortium (ARC) (see
Section 9.9 – Pooled Results of the Global RESOLUTE Clinical Trial Program (RESOLUTE
FIM, RESOLUTE US, RESOLUTE AC, RESOLUTE International, RESOLUTE Japan) for more
inf ormation).
5.1 Pre- and Post-Procedure Antiplatelet Regimen
In the Med tronic RESOLUTE US Clinical Trial, RESOLUTE AC Clinical Trial, RESOLUTE International
Study, RESOLUTE First-In-Man (FIM) Clinical Trial and RESOLUTE Japan Clinical Trial, the protocol
sp ecified administration of clopidogrel or ticlopidine prior to the p rocedure and for a p eriod of at least 6
months post-procedure and up to 12 months in patients who were not at high risk of bleeding. Aspirin
was administered prior to the procedure concomitantly with clopidogrel or ticlopidine and then continued
indef initely to reduce the risk of thrombosis. In the Medtronic RESOLUTE US Primary Enrollment
Group, 95.9%, 93.8% and 46.6% of the patients remained on dual antiplatelet therapy at 6 months, 12
months and 60 months, respectively. In the RESOLUTE AC Clinical Trial, 93.1%, 84.2% and 11.0% of
the p atients remained on dual antiplatelet therapy at 6 months, 12 months and 60 months, respectively.
In the RESOLUTE International Study, 95.9%, 91.1% and 34.6% of the patients remained on dual
antiplatelet therapy at 6 months, 12 months and 36 months, respectively. In the RESOLUTE FIM
Clinical Trial, 79.1%, 58.1% and 39.4% of the patients remained on dual antiplatelet therapy at 6
months, 12 mo nths and 60 months,
respectively. In the RESOLUTE Japan Clinical Trial, 99.0%, 94.9%
and 62.5% of the patients remained on dual antiplatelet therapy at 6 months, 12 months and 60 months,
resp ectively. In the RESOLUTE 38 mm Length Group, 92.8%, 91.4% and 61.5% of the patients
remained o n d ual antiplatelet therapy at 6 months, 12 months and 60 months, respectively. See
Section
9 - CLINICAL STUDIES, for more information.
5.1.1 Oral Antiplatelet Therapy
Dual antiplatelet therapy (DAPT) using a combination treatment of aspirin with a P2YP12 platelet inhibitor
af ter percutaneous coronary intervention (PCI), reduces the risk of stent thrombosis and ischemic cardiac
events, b ut may increase the risk of bleeding complications. The optimal duration of DAPT, specifically a
P2Y12 platelet inhibitor in addition to aspirin, following DES implantation is unknown, and DES
thrombosis may still occur despite continued therapy. It is very important that the patient is compliant with
the p o st-procedural antiplatelet recommendations.
1
Per 2016 ACC/AHA guidelines,
a daily aspirin dose of 81 mg is recommended indefinitely after PCI. A
P2Y12 platelet inhibitor should be g iven daily for at least 6 months in stable ischemic heart disease patients
and f o r at least 12 months in patients with acute coronary syndrome (ACS).
In p ivo tal trials of current generation DES, subjects were prescribed DAPT for at least 6 months postprocedure, and most patients who were not at high risk of bleeding used DAPT for at least 12 months.
Consistent with the 2016 ACC/AHA guidelines,
1
and the DAPT Study,2 longer duration of DAPT may be
co nsidered in patients who have tolerated DAPT without a bleeding complication and who are not at high
1
Levine GN, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A
Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;
doi:10.1016/j.jacc.2016.03.513. For full text, please refer to the following website:
http://content.onlinejacc.org/article.aspx?doi=10.1016/j.jacc.2016.03.513
6
bleeding risk. In patients who are at a hig h risk of bleeding or who develop significant bleeding during
DAPT treatment, these guidelines suggest that a sho rter DAPT d uration may be reasonable. However,
def initive evidence supporting the safety of short DAPT duration has not been established in p rospective
clinical studies.
Decisions about duration of DAPT are best made on an ind ividual basis and should integrate clinical
judgment, assessment of ischemic and bleeding risks, and p atient preference.
Premature discontinuation or interruption of prescribed antiplatelet medication could result in an
increased risk of stent thrombosis, MI or death.
Prio r to PCI, if premature discontinuation of antiplatelet therapy is anticipated, physicians should
caref ully evaluate with the patient whether a DES and its associated recommended DAPT regimen is
the ap p ropriate PCI choice.
Following PCI, if elective noncardiac surgery requiring suspension of antiplatelet therapy is
co nsidered, the risks and benefits of the procedure should be weighed against the possible risk
associated with interruption of antiplatelet therapy.
Patients who require premature DAPT discontinuation should be carefully monitored for cardiac events.
At the d iscretion of the patient’s treating physician(s), the antiplatelet therapy should be restarted as
so o n as possible.
5.2 Use of Multiple Stents
The lo ng -term effects of zotarolimus are currently unknown. The extent of the patient’s exposure to
zotarolimus drug and the stent and polymer coating is directly related to the number of stents and total
stent length implanted.
When multip le stents are required, stent materials should be of similar composition. Placing multiple
stents of different materials in contact with each other may increase potential for corrosion. To avoid the
possibility of dissimilar metal corrosion, do not implant stents of different materials in tandem where
overlap or contact is possible.
Potential interactions of the Resolute Integrity stent with other drug-eluting or coated stents have not
been evaluated and should be avoided whenever possible.
When using two wires, care should be taken when introducing, torquing and removing one or both
guidewires to avoid entanglement. In this situation, it is recommended that one guidewire be completely
withd rawn f rom the patient before removing any additional equipment.
5.3 Use in Conjunction with Other Procedures
The saf ety and effectiveness of using mechanical atherectomy devices (directional atherectomy
catheters, rotational atherectomy catheters) or laser angioplasty catheters in conjunction with Resolute
Integrity stent implantation have not been established.
5.4 Brachytherapy
The saf ety and effectiveness of the Resolute Integrity stent in target lesions treated patients with prior
brachytherapy, or the use of brachytherapy to treat in-stent restenosis of a Resolute Integrity stent, have
not b een established.
5.5 Use in Special Populations
Information on use of the Resolute Integrity stent in certain special patient populations is derived from
clinical studies of the Resolute stent system, which uses the same drug (zotarolimus) – see Section 7
OVERVIEW OF CLINICAL TRIALS for a d escription of the other features of the Resolute stent system
co mpared to the Resolute Integrity stent system.
5.5.1 Pregnancy
Pregnancy Category C. See Section 6.6 Pregnancy under Drug Information. There are no well-
co ntrolled studies in p regnant women or men intending to father children. The Resolute Integrity stent
2
Mauri L, et al. Twelve or 30 Months of Dual Antiplatelet Therapy After Drug-Eluting Stents. N Engl J Med. 2014;371:2155–66.
7
sho uld be used during pregnancy only if the potential benefit outweighs the potential risk to the embryo
or fetus. Effective contraception should be initiated before implanting a Resolute Integrity stent and for 1
year af ter implantation.
5.5.2 Lactation
It is not kno wn whether zotarolimus is excreted in human milk. The pharmacokinetic and safety profiles
of zotarolimus in infants are not known. Because many drugs are excreted in human milk and because
of the potential for adverse reactions in nursing infants from zotarolimus, a decision should be made
whether to discontinue nursing or to implant a Resolute Integrity stent, taking into account the
imp o rtance of the stent to the mother. See Section 6.7 – Lactation under Drug Information.
5.5.3 Gender
Clinical studies of the Resolute stent did not suggest any significant differences in safety and
ef f ectiveness for male and female patients. See Section 9.9.1 – Gender Analysis from the
RESOLUTE Pooled On-label Dataset.
5.5.4 Ethnicity
Clinical studies of the Resolute stent did not include sufficient numbers of patients to assess for
dif ferences in safety and effectiveness due to ethnicity.
5.5.5
The saf ety and effectiveness of the Resolute Integrity stent in patients below the age of 18 years have
not b een established.
5.5.6 Geriatric Use
Clinical studies of the Resolute stent did not have an upper age limit. Among the 1242 patients treated
with the Resolute stent in the Resolute US Main Study that included 2.25 - 3.5 mm stents, 617 patients
were ag e 65 o r o lder and 88 patients were age 80 or older. A post hoc analysis of patients treated with
the Resolute stent showed no significant differences between subjects under age 65 vs. age 65 and
older in the rates of cardiac death, target vessel MI, target lesion revascularization, ARC definite or
probable stent thrombosis, or target lesion failure at 12 months. The rate of all-cause death at 12
months was 0.3% in patients under age 65 vs. 1.8% in patients age 65 or older.
Pediatric Use
5.5.7 Lesion/Vessel Characteristics
The saf ety and effectiveness of the Resolute Integrity stent have not been established in the cerebral,
caro tid , or peripheral vasculature or in the f ollowing coronary disease patient populations:
• Patients with coronary artery reference vessel diameters <2.25 mm or >4.2 mm.
• Patients with coronary artery lesions longer than 35 mm or requiring more than one Resolute
Integrity stent.
• Patients with evidence of an acute MI within 72 hours of intended stent implantation.
• Patients with vessel thrombus at the lesion site.
• Patients with lesions located in a saphenous vein graft, in the left main coronary artery, ostial
lesions, or bifurcation lesions.
• Patients with diffuse disease or poor flow distal to identified lesions.
• Patients with tortuous vessels in the region of the target vessel or proximal to the lesion.
• Patients with in-stent restenosis.
• Patients with moderate or severe lesion calcification at the target lesion.
• Patients with 3 vessel disease.
• Patients with a left ventricular ejection fraction of <30%.
• Patients with a serum creatinine of >2.5 mg/dl.
• Patients with longer than 24 months of follow-up.
5.6 Drug Interactions
The ef f ect of potential drug interactions on the safety or effectiveness of the Resolute Integrity stent has
not b een investigated. While no specific clinical data are available, drugs, like sirolimus, that act through
the same b inding protein (FKBP12) may interfere with the efficacy of zotarolimus. Zotarolimus is
metabolized by CYP3A4, a human cytochrome P450 enzyme. When administered concomitantly with
8
200 mg keto conazole bid, a strong inhibitor of CYP3A4, zotarolimus produces less than a 2-fold
increase in AUC
with no ef fect on C
0-i nf
max
drug interactions when deciding to place a Resolute Integrity stent in a patient who is taking drugs that
are kno wn substrates or inhibitors of the cytochrome P450 isoenzyme CYP3A4. Systemic exposure of
zotarolimus should also be taken into consideration if the patient is treated concomitantly with systemic
immunosuppressive therapy.
Formal drug interaction studies have not been conducted with the Resolute Integrity stent.
5.7 Magnetic Resonance Imaging (MRI)
Non-clinical testing has demonstrated the Resolute Integrity stent up to a total length of 120 mm is MR
Conditional. It can be scanned safely under the following conditions:
• Static magnetic field of 1.5 and 3 Tesla.
• Spatial gradient field of 1000 G/cm or less
• Maximum whole body averaged specific absorption rate (SAR) of 2.0 W/kg or less under normal
operating mode only, for 15 minutes of scanning.
1.5 T
Based on non-clinical testing and modeling, a 38 mm Resolute Integrity stent was calculated to produce
an in-vivo temperature rise of less than 2.35°C, and overlapped stents with a maximum length of 120
mm were calculated to produce an in-vivo temperature rise of less than 3.87°C at a maximum whole
body averaged specific absorption rate (SAR) of 2.0 W/kg for 15 minutes of MR scanning per sequence
in a 64 MHz whole body transmit coil, which corresponds to a static field of 1.5 Tesla. These
calculations do not take into consideration the cooling effects of p erfusion and blood flow. The maximum
whole body averaged specific absorption rate (SAR) was derived by calculation.
. Therefore, consideration should be given to the potential for
3 T
Based on non-clinical testing and modeling, a 38 mm Resolute Integrity stent was calculated to produce
an in-vivo temperature rise of less than 3.29°C and overlapped stents with a maximum length of 120
mm were calculated to produce an in-vivo temperature rise of less than 3.95°C at a maximum whole
body averaged specific absorption rate (SAR) of 2.0 W/kg for 15 minutes of MR scanning per sequence
in a 3 T GE SIGNA HDx with software version 14\LX\MR release 14.0.M5A.0828.b. These calculations
do not take into consideration the cooling effects of perfusion and blood flow. The maximum whole body
averag ed specific absorption rate (SAR) was derived by calculation.
1.5 T and 3 T
The Resolute Integrity stent should not move or migrate when exposed to MR scanning immediately
post-implantation. MRI at 3 Tesla and 1.5 Tesla may be performed immediately following the
imp lantation of the stent. Non-clinical testing at field strength greater than 3 Tesla has not been
performed to evaluate stent migration and heating. MR image quality may be compromised if the area of
interest is in the same area or relatively close to the position of the d evice. Therefore, it may be
necessary to optimize MR imaging parameters for the presence of the stent. The image artifact extends
approximately 1 cm from the device, both inside and outside the device lumen when scanned in nonclinical testing using the spin echo and g radient echo sequences specified in ASTM F2119-01; the
device lumen was always observed during scanning. This testing was completed using a GE SIGNA
HDx with software version 14\LX\MR release 14.0.M5A.0828.b.
5.8 Stent Handling Precautions
• Fo r sing le use only. The Reso lute Integrity System is provided sterile. Do not resterilize or reuse this
product. Note the “Use By” date on the product label. Do not use if package or product has been
opened or damaged.
• Only the contents of the pouch should be considered sterile. The outside surface of the pouch is not
sterile.
• Do not remove the contents of the pouch until the device will be used immediately.
• Do not remove the stent from the delivery balloon; removal may damage the stent and polymer
co ating and /or lead to stent embolization. The Reso lute Integrity System is intended to perform as a
system. The stent is not designed to be crimped onto another delivery device.
9
• Special care must be taken not to handle or in any way disrupt the stent on the balloon. This is most
imp o rtant while removing the catheter from the packaging, placing it over the guidewire, and
advancing it through the rotating hemostatic valve and guide catheter hub.
• Do not try to straighten a kinked shaft or hypotube. Straightening a kinked metal shaft may result in
breakag e of the shaft.
• Stent manip ulation (e.g., rolling the mounted stent with your fingers) may cause coating damage,
co ntamination or dislodgement of the stent from the delivery system balloon.
• The Resolute Integrity System must not be exposed to any direct handling or contact with liquids
prior to preparation and delivery as the coating may be susceptible to damage or premature drug
elution.
• Use only the ap propriate balloon inflation media. Do not use air or any gaseous medium to inflate
the b alloon as this may cause uneven expansion and difficulty in deployment of the stent.
• The Resolute Integrity stent delivery system should not be used in conjunction with any other stents
or for post-dilatation.
5.9 Stent Placement Precautions
• The vessel must be pre-dilated with an appropriately sized balloon. Refer to the pre-dilatation
ballo on sizing described in Section 13.5 – Delivery Procedure. Failure to do so may increase the
risk o f placement difficulty and procedural complications.
• Do not prepare or pre-inflate the balloon prior to stent deployment other than as directed. Use the
ballo on p urging technique described in Section 13 – DIRECTIONS FOR USE.
• Guide catheters used must have lumen sizes that are suitable to accommodate the stent delivery
system (see Device Component Description in Table 1-1).
• Af ter preparation of the stent delivery system, do not induce negative pressure on the delivery
catheter prior to placement of the stent across the lesion. This may cause premature dislodgment of
the stent f rom the balloon or delivery difficulties.
• Ballo o n pressures should be monitored during inflation. Do not exceed rated burst pressure as
indicated on the p roduct label. Use of pressures higher than those specified on the product label
may result in a ruptured balloon with possible intimal damage and dissection.
• In small or diffusely diseased vessels, the use of hig h balloon inflation pressures may over-expand
the vessel distal to the stent and could result in vessel dissection.
• Implanting a stent may lead to a dissection of the vessel distal and/or proximal to the stented portion
and may cause acute closure of the vessel requiring additional intervention (e.g., CABG, further
dilatation, placement of additional stents, or o ther intervention).
• Do not expand the stent if it is not properly positioned in the vessel (see Section 5.10
PRECAUTI ONS-Stent/ System Removal Precautions).
• Placement of the stent has the potential to compromise side branch patency.
• Do not attempt to pull an unexpanded stent back through the guide catheter, as dislodgement of the
stent f rom the balloon may occur. Remove as a single unit per instructions in Section 5.10
PRECAUTI ONS -Stent/System Removal Precautions.
• Under-expansion of the stent may result in stent movement. Care must be taken to properly size
the stent to ensure that the stent is in full contact with the arterial wall upon deflation of the balloon.
• Stent retrieval methods (e.g., use of additional wires, snares and/or forceps) may result in additional
trauma to the coronary vasculature and/or the vascular access site. Complications may include
bleeding, hematoma, or pseudoaneurysm.
• Ensure f ull coverage of the entire lesion/dissection site so that there are no gaps between stents.
• Administration of appropriate anticoagulant, antiplatelet and coronary vasodilator therapy is critical
to successful stent implantation.
5.10 Stent/System Removal Precautions
If removal of a stent system is required prior to deployment, ensure that the guide catheter is coaxially
positioned relative to the stent delivery system and cautiously withdraw the stent delivery system into
the g uide catheter. Should unusual resistance be felt at any time when withdrawing the stent towards
the g uide catheter, the stent delivery system and the guide catheter should be removed as a single unit.
This must be done under direct visualization with fluoroscopy.
When removing the stent delivery system and guide catheter as a single unit:
10
• Do not retract the stent delivery system into the guide catheter. Maintain guidewire p lacement
acro ss the lesion and carefully pull back the stent delivery system until the p roximal balloon marker
of the stent delivery system is aligned with the d istal tip of the guide catheter.
• The system should be pulled back into the descending aorta toward the arterial sheath. As the distal
end of the guide catheter enters into the arterial sheath, the catheter will straighten, allowing safe
withd rawal of the stent delivery system into the guide catheter and the subsequent removal of the
stent delivery system and the guide catheter from the arterial sheath.
Failure to f ollow these steps and/or applying excessive force to the stent delivery system can potentially
result in loss or damage to the stent and/or stent delivery system components such as the balloon.
5.11 Post-Procedure
• Care must be exercised when crossing a newly d eployed stent with an intravascular ultrasound
(IVUS) catheter, an optical coherence tomography (OCT) catheter, a coronary guidewire or a
ballo on catheter to avoid disrupting the stent placement, apposition, geometry, and/or coating.
• Post-dilatation: All efforts should be made to assure that the stent is not under dilated. If the
deployed stent is not fully apposed to the vessel wall, the stent may be expanded further with a
larger diameter balloon that is slightly shorter (about 2 mm) than the stent. The post-dilatation can
be done using a low-profile, high pressure, non-compliant balloon catheter. The balloon should not
extend outside of the stented region. Do not use the stent delivery balloon for post-dilatation.
• If p atient requires MR imaging, refer to Section 5.7 – Magnetic Resonance Imaging (MRI), above.
• Antiplatelet therapy should be administered post-procedure (see Precautions – Section 5.1 Pre-
and Post-Procedure Antiplatelet Regimen). Patients who require early discontinuation of
antiplatelet therapy (e.g., secondary to active bleeding), should be monitored carefully for cardiac
events. At the discretion of the patient's treating physician, antiplatelet therapy should be restarted
as soon as possible.
6 DRUG INFORMATION
6.1 Mechanisms of Action
The suggested mechanism of action of zotarolimus is to bind to FKBP12, leading to the formation of a
trimeric complex with the protein kinase mTOR (mammalian target of rapamycin), inhibiting its activity.
Inhibition of mTOR results in the inhibition of p rotein phosphorylation events associated with translation
of mRNA and cell cycle control.
6.2 Metabolism
Zotarolimus undergoes oxidative metabolism in the liver to form the demethyl and hydroxylated
metabolites of the parent drug. Further metabolism can lead to the formation of hydroxyl-demethyl and
dihydroxyl-demethyl metabolites. Enzymes of the CYP3A family are the major catalysts of oxidative
metabolism of zotarolimus. Zotarolimus is a competitive inhibitor of CYP3A-dependent activities;
however, the IC
values (3 μM and above) are many fold higher than the systemic concentrations
50
exp ected following implantation of a drug-eluting stent. The anticipated zotarolimus blood levels in
stented patients are expected to be less than 0.004 μM, suggesting that clinically significant drug-drug
interactions are unlikely.
6.3 Pharmacokinetics of the Resolute Stent
The pharmacokinetics information for the Resolute Integrity stent system is derived from a study
co nd ucted on the Resolute stent system. The Resolute Integrity stent system is similar to the Resolute
stent system with regards to the stent design, the stent coating technology (dosing and drug to polymer
ratio), and delivery system design and materials. Given these similarities and supportive bench and
animal study information, the pharmacokinetics information from the RESOLUTE FIM PK Sub-study, as
described b elow, is applicable to the Resolute Integrity stent system.
The pharmacokinetics (PK) of zotarolimus delivered from the Resolute Stent has been determined in
patients with coronary artery disease after stent implantation in the Medtronic RESOLUTE FIM Cl i ni cal
Trial. The d o se of zotarolimus was calculated per stent unit surface area and the key pharm aco ki netic
parameters d etermined from these patients are provided in Table 6-1.
11
Table 6-1: Zotarolimus Pharmacokinetics in the Medtronic RESOLUTE FIM Clinical Trial PK
Sub-study Patients after Im plantation of Resolute Zotarolimus-Eluting Coronary Stents
PK
Parameter Units
Group I
(128 μg)
N = 1†
Group IIa
(180 μg)
N = 11
Group IIIa
(240 μg)
N = 7
Cmax (ng/mL) 0.129 0.210 ± 0.062 0.300 ± 0.075 0.346 ± 0.133
Tmax (h) 1.00 0.9 ± 0.7 0.9 ± 0.5 0.8 ± 0.5
AUC0-last
AUC0-inf$
(ng•h/mL)
(ng•h/mL)
15.08 16.04 ± 4.74 35.89 ± 12.79 31.19 ± 17.69
41.89 39.09 ± 11.77 52.41 ± 12.57 80.12 ± 51.00
ȕ$ (1/h) 0.003 0.004 ± 0.001 0.004 ± 0.001 0.003 ± 0.002
‡,#
t½
(h) 263.4 195.5 ± 74.4 167.4 ± 29.7 208.3 ± 144.4
CL/F$ (L/h) 3.06 5.23 ± 2.55 4.80 ± 1.11 5.14 ± 3.55
Vdȕ/F$ (L) 1161.2 1449.3 ± 221.6 1181.2 ± 336.4 1658.6 ± 494.8
Notes
Maximum observed blood concentration a Primary dose groups
C
max
T
Time to C
max
AUC
0-last
AUC from time 0 to infinity (AUC
AUC
0-inf
t½ Harmonic mean half-life
CL/F Mean apparent clearance
Vdȕ/F Apparent volume of distribution $ Not a true sample
Area under the blood concentration-time curve
(AUC) from time 0 to time of last measurable
concentration
† No SD was reported when N = 1
max
‡ Harmonic mean ± pseudo-standard deviation
). # Not a true estimate of the elimination half-life as the
0-inf
drug release from the stent was not complete during the
course of the pharmacokinetic sampling
The results in Table 6-1 show that the pharmacokinetics of zotarolimus were linear in the primary doseproportionality evaluation (including dose groups with N > 1), 180, 240 and 300 μg, following the
imp lantation of the Resolute Stents as illustrated by dose proportional increases in maximum blood
co ncentration (C
measurable concentration (AUC
clearance (CL/F) and harmonic mean half-life (t
), area under the blood concentration-time curve (AUC) from time 0 to time of last
max
) and AUC from time 0 to infinity(AUC
0-l ast
) for the primary dose groups ranged from 4.80 to 5.23
1/2
). The mean apparent
0-i nf
L/h and 167.4 to 208.3 h, respectively. The mean time to reach peak systemic concentration (T
ranged from 0.8 to 0.9 h after stent implantation.
Group IVa
(300 μg)
N = 3
max
)
The data demonstrate dose proportionality and linearity similar to that seen with increasing zotarolimus
doses from the Endeavor stent and intravenous administration. Based on available zotarolimus
pharmacokinetic data, systemic safety margins of 78-fold have been established for the Resolute stent
at 380 μg due to the extended elution of zotarolimus from the BioLinx polymer.
6.4 Pharmacokinetics following Multi-dose Intravenous Administration of Zotarolimus
Zotarolimus pharmacokinetic activity has been determined following intravenous administration in
healthy subjects. Table 6-2 provides a summary of the p harmacokinetic analysis.
12
Table 6-2: Pharmacokinetic Parameters (Mean ± Standard Deviation) in Patients
Following Multi-dose Intravenous Administration of Zotarolimus
200 μg QD
PK
Parameters Units
Cmax (ng/mL)
Tmax (h) 1.05 ± 0.04¥ 1.03 ± 0.04 1.00 ± 0.14 1.05 ± 0.04 1.03 ± 0.04 1.03 ± 0.05
AUC0-24
t1/2$ (h)
CLb (L/h)
Notes
¥
N = 16;
$ Harmonic mean ± pseudo-standard deviation
b
Clearance data is calculated using compartmental methods.
All other data presented in Table 6-2 is calculated using non-compartmental methods.
(ng•h/mL)
N = 15
Day 1 Day 14 Day 1 Day 14 Day 1 Day 14
11.41±
¥
1.38
34.19 ±
¥
4.39
4.2 ± 0.6 4.2 ± 0.6 4.0 ± 0.9 4.0 ± 0.9 4.6 ± 0.4 4.6 ± 0.4
11.93 ±
1.25
47.70 ±
6.68
32.9 ± 6.8
68.43 ± 15.41
400 μg QD
N = 16
21.99 ± 3.79 23. 31± 3.15 37.72 ± 7.00 41.79 ± 6.68
100.47 ±
18.02
37.6 ± 4.5
When administered intravenously for 14 consecutive days, zotarolimus showed dose proportionality.
Renal excretion is not a major route of elimination for zotarolimus as approximately 0.1% of the dose
was excreted as unchanged drug in the urine per day. In multiple doses of 200, 400 and 800 μg,
zotarolimus was generally well tolerated by the subjects. No clinically significant abnormalities in
physical examinations, vital signs or laboratory measurements were observed during the study.
6.5 Mutagenesis, Carcinogenicity and Reproductive Toxicology
6.5.1 Mutagenesis
Zotarolimus was not genotoxic in the in v itro bacterial reverse mutation assay, the human peripheral
lymphocyte chromosomal aberration assay, or the in vivo mouse micronucleus assay.
800 μg QD
N = 16
123.48 ± 13.34 174.43 ± 19.88
36.0 ± 4.7
6.5.2 Carcinogenicity
No long-term studies in animals have been performed to evaluate the carcinogenic potential of
zotarolimus. The carcinogenic potential of the Resolute stent is expected to be minimal based on the
types and quantities of materials present.
6.5.3 Reproductive Toxicology
No effect on fertility or early embryonic development in female rats was observed following the IV
administration of zotarolimus at dosages up to 100 μg/kg/day (approximately 19 times the cumulative
blood exposure provided by Resolute stents coated with 300 μg zotarolimus).
For male rats, there was no effect on the fertility rate at IV dosages up to 30 μg/kg/day (approximately
21 times the cumulative blood exposure provided by Resolute stents coated with 300 μg zotarolimus).
Reduced sperm counts and motility, and failure in sperm release were observed in male rats following
the IV ad ministration of zotarolimus for 28 days at dosages of >30 μg/kg/day. Testicular germ cell
degeneration and histological lesions were observed in rats following IV dosages of 30 μg/kg/day and
above.
6.6 Pregnancy
Pregnancy Category C: There are no well-controlled studies in pregnant women, lactating women, or
men intending to father children for this product.
Administration of zotarolimus to pregnant female rats in a developmental toxicity study at an intravenous
dosage of 60 μg/kg/day resulted in embryolethality. Fetal ossification delays were also observed at this
dosage, but no major fetal malformations or minor fetal anomalies were observed in this study. A 60
μg/kg/day dose in rats results in approximately 47 times the maximum blood level and about 11 times
the cumulative blood exposure in patients receiving Resolute Integrity stents coated with 300 μg
zotarolimus total dose.
13
No embryo-fetal effects were observed in pregnant rabbits administered zotarolimus in a developmental
to xicity study at intravenous dosages up to 100 μg/kg/day. This dose in rabbits results in approximately
215 times the maximum blood level and about 37 times the cumulative blood exposure in patients
receiving Resolute Integrity stents coated with 300 μg zotarolimus total dose.
Ef fective contraception should be initiated before implanting a Resolute Integrity stent and continued for
one year p o st-stent implantation. The Resolute Integrity stent should be used in pregnant women only if
potential benefits justify potential risks.
6.7 Lactation
It is not kno wn whether zotarolimus is excreted in human milk. The potential adverse reactions in
nursing inf ants from zotarolimus have not been determined. The pharmacokinetic and safety profiles of
zotarolimus in infants are not known. Because many drugs are excreted in human milk and because of
the p o tential for adverse reactions in nursing infants from zotarolimus, a decision should be made
whether to discontinue nursing or to implant the stent, taking into account the importance of the stent to
the mother.
7 OVERVIEW OF CLINICAL TRIALS
Clinical Trials in support of Pre-market Approval:
The princip al safety and effectiveness information for the Resolute Integrity stent system is derived from
a series o f clinical trials conducted on the Resolute stent system. The Resolute stent system consists of
a co b alt alloy bare metal stent, the zotarolimus and BioLinx stent coating, and the Sprint delivery
system. The Resolute Integrity stent mounted on the MicroTrac delivery system is similar to the
Resolute stent mounted on the Sprint delivery system with regard to the stent design, the stent coating
technology (drug concentration and drug to polymer ratio), and delivery system design and materials.
The Resolute Integrity stent is manufactured from a single wire whereas the Resolute stent is formed
f rom laser fused elements. The Resolute Integrity stent is mounted on the MicroTrac delivery system,
which differs fro m the Sprint delivery system with regard to the catheter manufacturing, shaft and tip
design, and stent crimping process. Given the similarities between the Resolute stent system and the
Resolute Integrity stent system, and supportive bench and animal study information, the findings from
the RESOLUTE clinical studies, as described below, are applicable to the Resolute Integrity stent
system.
The princip al safety and effectiveness information for the Resolute stent was derived from the Global
RESOLUTE Clinical Trial Program, which consists of the following clinical trials – the RESOLUTE
United States Clinical Trial(R-US), the RESOLUTE All-Comers Clinical Trial(R-AC), the RESOLUTE
International Study(R-Int), the RESOLUTE First-in-Man (FIM) Clinical Trial and the RESOLUTE Japan
Clinical Trial(R-J). These f ive studies have evaluated the performance of the Resolute stent in improving
co ro nary luminal diameters in patients, including those with diabetes mellitus, with symptomatic
ischemic heart disease due to de novo lesions of length 35 mm in native coronary arteries with
reference vessel diameters of 2.25 mm to 4.2 mm. Key elements of these studies are summarized
below and in
R-US and the RESOLUTE Asia study (R-Asia) (For 38 mm Length Group data see Tab le 7-1).
The RESOLUTE United States (RESOLUTE US) Clinical Trial is a prospective, multi-center, nonrandomized trial that evaluated the safety and effectiveness of the Resolute stent for treatment of de
novo lesions in native coronary artery(ies) with reference vessel diameters (RVD) ranging from 2.25 to
4.2 mm. The RESOLUTE US Clinical Trial is the pivotal trial of the overall Global RESOLUTE Clinical
Trial Program. The RESOLUTE US Trial included the following:
• The 2.25 to 3.5 mm Main Study: The primary endpoint was Target Lesion Failure (TLF) at 12
• The 2.25 mm cohort analysis, in which the cohort was derived from subjects treated with the
• The 2.25 to 3.5 mm Angio/IVUS Sub-study: The primary endpoint was in-stent late lumen loss
Table 7-1. The Resolute 38 mm Length Group was derived from subjects enrolled in the
months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (MI) or
clinically-driven Target Lesion Revascularization (TLR).
2.25 mm Resolute stent in the 2.25 to 3.5 mm Main Study and the 2.25 to 3.5 mm Angio/IVUS
sub -study. The primary endpoint was TLF at 12 months post-procedure.
(LL) at 8 months post-procedure as measured by quantitative coronary angiography (QCA).
14
• The 4.0 mm stent Sub-study: The primary endpoint was in-segment late LL at 8 months post-
procedure as measured by QCA.
The total study population of the primary enrollment group (consisting of all subjects enrolled in the four
studies listed above) consisted of 1402 subjects at 116 investigational sites in the United States.
Post-procedure, subjects were to receive aspirin indefinitely and clopidogrel/ticlopidine for a minimum of
6 months and up to 12 months in subjects who were not at a high risk of bleeding.
The 38 mm Length Group: In addition to the primary enrollment group, the 38 mm Length Group is
made up of 38 mm subjects from RESOLUTE US 38 mm Length Sub-study pooled with subjects from
the RESOLUTE Asia (R-Asia) 38 mm cohort (see description of the R-Asia study below).
• The primary endpoint was Target Lesion Failure (TLF) at 12 mo nths post-procedure, defined as
Cardiac Death, Target Vessel Myocardial Infarction (MI) or clinically-driven Target Lesion
Revascularization (TLR).
The RESOLUTE All-Comers (RESOLUTE AC) Clinical Trial is a prospective, multi-center, two-arm
randomized, non-inferiority trial that compared the Resolute stent to a control DES (the Xience V
®
stent). The eligibility criteria reflected an ‘all-comers’ patient population. A total of 2292 subjects were
enrolled at 17 clinical research sites from 11 countries in Western Europe (Switzerland, Belgium,
Netherland s, Denmark, France, Germany, Italy, Spain, United Kingdom, Israel, and Poland). The
primary endpoint was TLF defined as the composite of Cardiac Death, MI (not clearly attributable to a
non-target vessel), or clinically indicated TLR within 12 months post-implantation. Post-procedure,
sub jects were to receive aspirin indefinitely and clopidogrel/ticlopidine for a minimum of 6 months and
up to 12 months in subjects who were not at a high risk of b leeding.
The RESOLUTE International (RESOLUTE Int) study is a prospective, multi-center, non-randomized,
single-arm o bservational study with all enrolled subjects treated according to routine practices at
participating hospitals. A total of 2349 subjects were enrolled at 88 clinical research sites from 17
co untries distributed over Europe, Asia, Africa and South America. The primary objective of this study
was to evaluate the safety and clinical performance of the Resolute stent in an ‘all-comers’ patient
population. The primary endpoint was the composite of Cardiac Death and MI (not clearly attributable to
a non-target vessel) at 12 mo nths post-implantation. Post-procedure, subjects were to receive aspirin
indef initely and clopidogrel/ticlopidine for a minimum of 6 months and up to 12 months in subjects who
were no t at a high risk of b leeding.
The RESOLUTE FIM Clinical Trial is the first-in-human study evaluating the Resolute stent. RESOLUTE
FIM is a non-randomized, prospective, multi-center, single-arm trial. The purpose of the trial was to
assess the initial safety of the Resolute stent. A total of 139 subjects were enrolled at 12 investigative
sites in Australia and New Zealand. The primary endpoint was in-stent late lumen loss (LL) at nine
months post-implantation measured by QCA. Post-procedure, subjects were to receive aspirin
indef initely and clopidogrel/ticlopidine for a minimum of 6 months. This trial had a subset of subjects
undergoing pharmacokinetic (PK) assessments (see Section
6.3 for the Pharmacokinetics of the
Resolute Stent).
The RESOLUTE Jap an Clinical Trial is a prospective, multi-center, non-randomized, single-arm trial. A
to tal o f 100 subjects were enrolled at 14 investigational sites in Japan. The primary endpoint was instent late lumen loss (LL) at 8 months post-procedure as measured by QCA. Post-procedure, subjects
were to receive aspirin indefinitely and clopidogrel/ticlopidine for a minimum of 6 months and up to 12
months in subjects who were not at a high risk of bleeding.
The RESOLUTE Asia (R Asia) study is a prospective, multi-center, non-randomized study. The primary
objective of this study was to document the safety and effectiveness of the Endeavor Resolute
Zotarolimus-Eluting Coronary Stent System in a patient population with long lesion(s). The Primary
endpoint for the 38 mm cohort was target lesion failure (TLF) at 12 months post-procedure, defined as
co mposite of cardiac death, target vessel myocardial infarction (Q wave and non-Q wave) or clinicallydriven target lesion revascularization (TLR) by percutaneous or surgical methods. The RESOLUTE
Asia trial was designed to be included in the p ooled dataset for the RESOLUTE 38 mm Length Group
(38 mm subjects from RESOLUTE US and RESOLUTE Asia). A total of 109 subjects were enrolled in
the 38 mm cohort across 17 clinical research sites from six (6) co untries throughout Asia.
15
All the RESOLUTE clinical trials utilized an independent Clinical Events Committee (CEC) for
adjudication of the clinical events. The definitions of clinical events were consistent across the clinical
trials, and the event adjudication process was harmonized to ensure consistency and comparability of
the d ata. All clinical trials had oversight by a Data and Safety Monitoring Board (DSMB). All trials had
data monitored for verification and accuracy. Independent Angiographic Core Labs were utilized for
angiographic and IVUS endpoints.
Post-market Approval Study:
The RESOLUTE INTEGRITY US Post Market Study is a prospective, multi-center evaluation of the
procedural and clinical outcomes of subjects that are treated with the commercially available Medtronic
Resolute Integ rity Zotarolimus-Eluting Coronary Stent System. The objective of this study is to assess
the saf ety and efficacy of the Resolute Integrity stent for the treatment of de novo lesions in native
co ro nary arteries with a reference vessel diameter (RVD) of 2.25 mm to 4.2 mm in two groups of
patients, specifically those patients receiving stents mm in leng th, referred to as the Primary
Enrollment Group (PEG) and those patients who receive extended length stents (34 mm or 38 mm)
referred to as the Extended Length (XL) Sub-study. The primary endpoint for this study is composite
rate of cardiac death and target vessel myocardial infarction (MI) at 12 months.
Table 7-1 summarizes the clinical trial designs for the Global RESOLUTE Clinical Trial Program and
Post-market Approval Study.
16
j
p
p
)
g
5
tr eated or les ion length
separate target vessels
US (XL Sub-study)
RES OLUTE INTE GRI TY
P rospect ive
M ulti- cente r
Non- randomized
P ost approval
4
Pos t-mar ket A pprova l Study
(PEG)
RES OLUTE INTE GRI TY U S
P rospect ive
M ulti- cente r
Non- randomized
P ost approval
38 mm Cohort
RESOLUTE Asia
P rospect ive
M ulti- cente r
Non- randomized
tar get lesions located in
Single t arget les ion or t wo
XL:
vessels
lesions locat ed in separate t arget
PEG:
Single target lesion or two target
in separat e tar get v essels
Single or two de novo lesions locat ed
Lesion(s) length ≤35 mm
Target vessel with RVD between 3.0 to
Target lesion mm
Target lesion mm
4.0 mm
Tar get ves sel wit h RVD bet ween
between 2. 25 to 4.2 mm .
Target vessel with RVD
2.25 t o 4.2 mm.
of up t o two lesions
second lesion RVD (2.25 to 4.2 mm), if
Pat ients m ay have r eceived t reatment
St ent Lengt h:
34-38 mm
St ent diam eter:
3.0 – 4. 0 mm
St ent lengt h:
St ent diam eter:
2.25 – 4. 0 mm
et vessels.
the lesions were located in separate
tar
St ent diam eter:
3.0 – 4. 0 mm
Resolute Integrity stent on the
8 – 30 mm
Resolute Integrity stent on the Rapid
St ent Lengt h: 38 m m
Resolut e Stent on t he Rapid Exc hange
Aspirin indefinitely and
clopidogr el/ tic lopidine f or
mont hs in all subject s, up to 12
Aspir in indefinitely and
Aspir in indefinitely and
mont hs if t olerated
tolerated
clopidogr el/ tic lopidine f or months
in all subject s, up t o 12 months if
clopidogr el/ tic lopidine, fo r mont hs in all
subject s, up to 12 m onths if tolerat ed
Rapid Exc hange Micr oTr ac
Deliver y S yst em
Exc hange Micr oTr ac Delivery Sys tem
Sprint Delivery System
RESOLUTE Japan
Prospective
M ulti- cente r
Non- randomized
Single-arm
His torical c ontrolled t rial
3
RES OLUTE FIM
Prospective
Mult i-cent er
Non-random ized
Single-arm
Hist oric al cont rolled tr ial
PK Assessment
Table 7-1: Clinical Trial Comparisons
2
RESOLUTE Int
Pros pective
Mult i-cent er
1
Pr e-ma rk et Appr oval Studi es; Gl obal R ES OLUTE C lini cal Tri al P rogra m
Pros pect ive
Mult i-cent er
ulation
o
ect
Tot al: 2349 T otal: 139 T otal: 100 Total: 109 Total: 230 Tot al: 56
Non-random ized
Single-arm
Obs ervat ional st udy
Real World sub
Tot al: 2292
(1: 1 Resolute v s. Xience V)
Randomiz ed
T wo-ar m, non-infer iorit y t rial
Real World subject populat ion
(Resolut e: 1140, Xience V: 1152)
located in s eparat e coronary
art eries
Lesion(s) length ≤27 mm
between 2. 5 to 3.5 mm
Target vessel with RVD
Single or two de novo lesions
8 – 30 mm
St ent lengt h:
St ent diam eter:
2.5 – 3. 5 mm
Resolute Stent on the Rapid
Exc hange Sprint Delivery Sys tem
Aspir in indefinitely and
mont hs if t olerated
clopidogr el/ tic lopidine f or
mont hs in all subject s, up to 12
17
and 3.5 m m
Single de novo lesion
Lesion length f rom 14 to 27 m m
Target vessel with RVD between 2.5
2.25 t o 4.0 mm
lesion length
lesion(s)/ vessel(s) treated or
No limit ation t o number of
Tar get ves sel wit h RVD bet ween
between 2. 25 to 4.0 mm .
lesion length
lesion(s) / v essel(s ) t reat ed or
No limit ation t o number of
Target vessel with RVD
8 – 30 mm
St ent lengt h:
St ent diam eter:
2.5 – 3. 5 mm
St ent lengt h:
St ent diam eter:
2.25 – 4. 0 mm
St ent lengt h:
St ent diam eter:
2.25 – 4. 0 mm
Resolut e Stent on t he Rapid Exc hange
8 – 38 mm
Resolute Stent on the Rapid
8 – 30 mm
Resolute Stent on the Rapid
Aspir in indefinitely and
Aspir in indefinitely and
Aspir in indefinitely and
clopidogr el/t iclopidine mont hs
tolerated
clopidogr el/ tic lopidine f or months
in all subject s, up t o 12 months if
clopidogr el/ tic lopidine f or
mont hs in all subject s, up to 12
mont hs if t olerated
AV100 Deliv ery S yst em
Exc hange Sprint Delivery Sys tem
Exc hange Sprint Delivery Sys tem
subject s wit h 114 fr om
subject s
Angio/IVUS sub-study -
100 subject s
subject s 2. 25–3.5 m m
Tot al: 1516
-1242 subjects
- 2.25 m m Cohort- 150
- 4.0 mm Sub-study -60
- 38 mm Sub-s tudy 114
Numb er of
Subj ects
Enrolled
- 2.25–3. 5 mm Main S tudy
RESOLUTE US* RESOLUTE AC
Prospective
Mult i-cent er
Non-random ized
Hist oric al cont rolled tr ial*
Study Type
RESO LUTE US and 109
population was 223
study Total patient
subject s) ( 38 mm Sub-
from RESOLUTE Asia
located in s eparat e target
vessels
Single or two de novo lesions
Lesion(s) length ≤27 mm for the
Prim ary E nrollment Gr oup, ≤35
Lesion
between 2. 25 to 4.2 mm
Gr oup
mm f or the 38-m m Lengt h
Target vessel with RVD
Criteria
Enrollm ent G roup, 38 mm for the 38
St ent lengt h:
St ent diam eter:
2.25 – 4. 0 mm
8 – 30 mm f or the Primary
mm Lengt h Group
Resolute Stent on the Rapid
Exc hange Sprint Delivery Sys tem
Aspir in indefinitely and
clopidogr el/ tic lopidine f or
mont hs in all subject s, up to 12
mont hs if t olerated
(Resolute)
Stent Sizes
Product Used
Post-
procedure
Ant ip latel et
Therapy
5
US (XL Sub-study)
RES OLUTE INTE GRI TY
4
Pos t-mar ket A pprova l Study
(PEG)
(Cont act) 2-3 year s (Cont act)
30 days ( Contac t); 6 months
(Cont act); 12 m onths (Clinic Visit
with 12-lead ECG ) and 2 years :
36-month follow-up is
complete
RES OLUTE INTE GRI TY U S
12-lead ECG ) and 2 years: (Cont act )
30 days ( Contac t); 6 months
(Cont act); 12 m onths (Clinic Visit with
24-month follow-up is
complete
38 mm Cohort
RESOLUTE Asia
30 days, 6, 9 (Clinical Visit ), 12, 18 months
then annually at 2 - 5 years
RESOLUTE Japan
telephone
6, 9 and 18 m onths and 2-5 years :
30 days and 12 m onths : c linical
8 mont hs: angiographic/ IV US
3
RES OLUTE FIM
subject subset ): clinical and
angiographic/ IVUS
30 days : c linical
Table 7-1: Clinical Trial Comparisons
2
6 mont hs and 1-5 y ears: telephone
4 (30 subject subset) and 9 mont hs (100
60-month follow-up is complete
complete.
18
60-month follow-up complete. 60-month follow-up is
RESOLUTE Int
30 days, 6 months, 1-3 year s: clinical
or telephone
1
Pr e-ma rk et Appr oval Studi es; Gl obal R ES OLUTE C lini cal Tri al P rogra m
13 mont hs (455 s ubject s ubset ):
and 9 mont hs: clinical; 6, 12 and 18
angiographic
mont hs, 2-5 years : t elephone
4.0 m m Sub- st udy: 8 months:
6 mont hs and 2-5 y ears:
clinical and angiographic; 6, 12 and
telephone
18 mont hs, 2-5 years : t elephone
2.25 - 3.5 m m Angio/ IVUS Sub-
Follow-up
38 mm Lengt h Sub-st udy : 30 days
(R-US ) and 9 mont hs clinical visit s
telephone
angiographic/ IV US 6, 12 and 18 m onths , 2-5 y ears:
st udy: 8 months: c linical and
30 days and 12 m onths : c linical
RESOLUTE US* RESOLUTE AC
2.25- 3.5 m m Main S tudy : 30 days
(pref erred) , or patient cont act 30
36-month follow-up is
complete.
60-month follow-up is
complete.
then annually at 2, 3, 4, 5 years
days ( R-As ia): 6, 12, 18 months
60-month follow-up is
complete.
551 subjects qual ified for
18-month follow-up.
Length Sub-study, and the 4.0 mm Sub-study have historical control designs. The 2.25 mm Subset outcomes were compared to a performanc e goal.
The term ‘Int’ refers to International.
The term ‘AC’ ref ers to All-comers.
Status
* The R ESOLUTE US trial is compos ed of four studies. The 2.5 - 3.5 mm s ubset of t he Main St udy, the 2. 25 – 3.5 mm Angio/ IVUS Sub-st udy, the 38 mm
The term ‘FIM’ refers to First-In-Man. 4 The term ‘PEG’ refers to Primary Enrollment Group. 5 The term ‘XL’ refers to Ex tended Length.
1
2
3
9
8 ADVERSE EVENTS
(
8.1 Observed Adverse Events
Observed adverse event experience with the Resolute stent is derived from the following five clinical
trials: the RESOLUTE US, RESOLUTE AC, RESOLUTE Int, RESOLUTE FIM and RESOLUTE Japan.
In ad d ition, the adverse event experience from the Resolute Integrity US Primary Enrollment Group
(PEG) Po st-market Approval Study and the Extended Length (XL) Sub-study have been included.
See Section 9 CLINICAL STUDIES for a more complete description of the trial designs and results.
The Glo b al RESOLUTE Clinical Trial Program has evaluated the performance of the Resolute stent in
sub jects, including those with diabetes mellitus, with symptomatic ischemic heart disease in de novo
lesions of native coronary arteries. The Resolute Integrity US Post-market Approval Study assessed the
saf ety and efficacy of the Resolute Integrity stent for the treatment of de novo lesions in native coronary
arteries. Principal adverse events are shown in Table 8-1 below.
Table 8-1: Principal Adverse Events from Post-Procedure Through Latest Available Follow-up
38 mm Length Sub-
study
R-US N = 114
R-Asia N = 109
Resol ute
(N = 223)
0.0% ( 0/223) 0.0% (0/ 230) 0. 0% (0/ 56)
Resol ute
(N = 1402)
1
RESOLUTE AC RESOLUTE Int RESOLUTE FIM RESOLUTE Japan
Resol ute
(N = 1140)
0.8% ( 9/1132) 0.4% (5/ 1142) 0. 5% (12/ 2337) 0. 0% (0/ 139) 0. 0% (0/100) 0.9% (2/222) 0.0% ( 0/226) 1. 8% (1/56)
3.5% ( 40/1132) 3. 8% (43/1142) 2. 5% (59/ 2337) 5. 8% (8/ 139) 4. 0% (4/100) 2.7% (6/222) 2.2% ( 5/226) 3. 6% (2/56)
1.9% ( 21/1132) 2. 2% (25/1142) 1. 2% (27/ 2337) 0. 0% (0/139) 1. 0% (1/100) 1.4% (3/222) 2.2% ( 5/226) 0. 0% (0/56)
Xi ence V
(N = 1152)
3.6% ( 42/1152)
Resol ute
(N = 2349)
2.2% ( 51/2349) 4. 3% (6/139) 2.0% (2/100) 3. 1% (7/223) 1. 7% (4/ 230) 1.8% ( 1/56)
Resol ute
(N = 139)
Resol ute
(N = 100)
RESOLUTE US
In-Hospital
TLF2 1. 3% (18/ 1402) 3. 7% (42/ 1140) 4.5% ( 52/1152) 2. 6% (61/2349) 4. 3% (6/ 139) 2.0% ( 2/100) 3. 6% (8/ 223) 1.7% (4/230) 1.8% (1/ 56)
3
TVF
MACE4 1.3% ( 18/1402) 3.8% (43/ 1140) 4. 9% (56/ 1152) 2. 7% (63/2349) 4.3% ( 6/139) 2. 0% (2/ 100) 3.6% ( 8/223) 1.7% (4/ 230) 1. 8% (1/ 56)
Tot al Death 0.0% (0/ 1402) 0.1% ( 1/1140) 0.8% (9/ 1152) 0.3% (7/ 2349) 0. 0% (0/ 139) 0. 0% (0/100) 0. 4% (1/223) 0.0% ( 0/230) 0. 0% (0/56)
Cardiac Death 0.0% ( 0/1402) 0.1% (1/ 1140) 0.6% (7/ 1152) 0. 3% (6/ 2349) 0.0% ( 0/139) 0. 0% (0/ 100) 0.4% ( 1/223) 0.0% (0/ 230) 0. 0% (0/56)
Non-Cardiac
Death
5
TVMI
Q wave MI 0.1% ( 1/1402) 0.3% (3/1140) 0.4% ( 5/1152) 0.3% (8/ 2349) 0.0% (0/ 139) 0.0% ( 0/100) 0. 4% (1/ 223) 0. 0% (0/230) 0.0% ( 0/56)
Non-Q Wave M I 1.1% (15/1402) 2.8% ( 32/1140) 3. 2% (37/1152) 1. 8% (43/ 2349) 4. 3% (6/ 139) 2. 0% (2/100) 2.7% (6/223) 1.7% ( 4/230) 1. 8% (1/56)
Cardiac Death or T VMI6 1.1% ( 16/1402) 3.2% (36/ 1140) 4. 0% (46/ 1152) 2. 4% (56/2349) 4.3% ( 6/139) 2. 0% (2/ 100) 3.6% (( 8/223) 1.7% ( 4/230) 1. 8% (1/56)
Clinically Driv en TVR7 0. 1% (2/ 1402) 0.9% ( 10/1140) 0. 9% (10/1152) 0. 4% 10/2349) 0.0% (0/139) 0. 0% (0/100) 0.0% ( 0/223) 0.4% (1/230) 0. 0% (0/56)
TLR8 0.1% ( 2/1402) 0.7% (8/1140) 0.7% ( 8/1152) 0. 4% (10/2349) 0. 0% (0/139) 0.0% ( 0/100) 0. 0% (0/ 223) 0.4% (1/230) 0.0% ( 0/56)
Non-TL TVR 0. 0% (0/ 1402) 0. 4% (4/ 1140) 0. 2% (2/ 1152) 0.0% ( 1/2349) 0.0% ( 0/139) 0. 0% (0/ 100)
ARC Def/Prob ST9 0.0% (0/1402) 0. 6% (7/ 1140) 0. 3% (4/1152) 0.4% ( 9/2349) 0.0% (0/ 139) 0.0% (0/100) 0. 4% (1/ 223) 0. 0% (0/ 230) 1.8% ( 1/56)
30 Day
MACE 1. 4% (20/1399) 4.4% ( 50/1133) 5. 2% (60/1146) 3. 3% (78/ 2345) 4.3% (6/139) 3. 0% (3/100) 4.5% ( 10/223) 3. 0% (7/230) 3. 6% (2/ 56)
12 Months
TLF 4.7% ( 65/1390) 8.1% (92/ 1132) 8. 5% (97/ 1142) 7.1% (165/2337) 7. 2% (10/139) 4.0% ( 4/100) 5. 4% (12/ 222) 4.9% ( 11/226) 7.1% (4/56)
TV F 6. 2% (86/ 1390) 8.9% (101/1132) 9.7% (111/ 1142) 7. 7% (180/ 2337) 7.2% (10/139) 5.0% (5/ 100) 6. 8% (15/ 222) 7.1% ( 16/226) 7.1% (4/56)
MACE 5.5% (77/ 1390) 8. 6% (97/1132) 9. 8% (112/ 1142) 8.3% (193/ 2337) 8.6% ( 12/139) 5.0% (5/ 100) 6.3% (14/222) 5. 8% (13/226) 8. 9% (5/56)
Tot al Death 1. 4% (19/ 1390) 1.6% ( 18/1132) 2.7% (31/ 1142) 2. 4% (57/ 2337) 2. 2% (3/139) 1. 0% (1/100) 0.9% (2/222) 1.8% ( 4/226) 1. 8% (1/56)
Cardiac Deat h 0. 7% (10/ 1390) 1.3% (15/1132) 1.7% ( 19/1142) 1. 5% (34/2337) 0. 7% (1/ 139) 0.0% ( 0/100) 0. 9% (2/ 222) 1.3% (3/226) 1.8% (1/56)
Non-Cardiac Death 0.6% ( 9/1390) 0.3% (3/1132) 1.1% ( 12/1142) 1. 0% (23/2337) 1. 4% (2/ 139) 1.0% ( 1/100) 0. 0% (0/ 222) 0.4% (1/226) 0.0% (0/56)
TV MI 1.3% ( 18/1390) 4.2% (48/ 1132) 4. 2% (48/ 1142) 3. 0% (71/2337) 5.8% ( 8/139) 4. 0% (4/ 100) 3.6% ( 8/222) 2.2% (5/ 226) 5. 4% (3/ 56)
Q wave MI
Non-Q Wave M I
Cardiac Deat h or TVM I 2. 0% (28/ 1390) 5. 3% (60/ 1132) 5.5% ( 63/1142) 4. 2% (99/2337) 6. 5% (9/ 139) 4.0% ( 4/100) 4. 5% (10/222) 3. 5% (8/ 226) 7. 1% (4/ 56)
Clinically Driven TV R 4.6% ( 64/1390) 4. 9% (55/1132) 4. 8% (55/ 1142) 4.2% (99/2337) 0.7% ( 1/139) 1. 0% (1/ 100) 2.7% ( 6/222) 4. 4% (10/226) 1. 8% (1/56)
TLR 2.9% (40/ 1390) 3. 9% (44/ 1132) 3.4% (39/1142) 3.5% ( 81/2337) 0. 7% (1/139) 0.0% (0/100) 1. 4% (3/222) 2. 2% (5/ 226) 1.8% ( 1/56)
Non-T L TV R 2.2% (30/ 1390)
ARC Def/ Prob ST
Latest Follow-up 60 Months 60 Months 36 Months 60 Months 60 Months 60 Months 24 Mon ths 36 Mo nth s
TLF 12. 3% (164/1329) 17.0% (191/ 1123) 16.2% ( 183/1133) 11.4% (261/2284) 11.0% (15/ 136) 6. 1% (6/98) 13.8% ( 30/217) 9.1% (20/ 219) 10.7% (6/ 56)
TV F 17. 5% (233/1329) 20.0% ( 225/1123) 19. 1% (216/ 1133) 12. 9% (294/ 2284) 13. 2% (18/ 136) 10.2% ( 10/98) 17. 1% (37/217) 12.3% ( 27/219) 12.5% (7/ 56)
MACE 18.0% (239/1329) 21.9% (246/ 1123) 21.6% (245/ 1133) 14. 4% (329/2284) 16. 2% (22/ 136) 14.3% (14/98) 17.5% ( 38/217) 11.0% (24/ 219) 17.9% (10/ 56)
Tot al Death 9. 6% (127/1329) 11.0% ( 123/1123) 10. 8% (122/ 1133) 6. 1% (139/ 2284) 6.6% ( 9/136) 7. 1% (7/ 98) 6.5% (14/ 217) 2. 7% (6/ 219) 3. 6% (2/ 56)
TV MI 3.2% ( 43/1329) 5.7% (64/ 1123) 5. 7% (65/ 1133) 3. 9% (89/2284) 6.6% ( 9/136) 4. 1% (4/98) 6.0% (13/ 217) 4. 1% (9/ 219) 5.4% (3/56)
9
Cardiac Deat h 4. 1% (55/ 1329) 6.5% (73/1123) 5.7% ( 65/1133) 3. 6% (82/2284) 1. 5% (2/ 136) 1.0% (1/ 98) 4.1% ( 9/217) 1. 8% (4/219) 1. 8% (1/ 56)
Non-Cardiac Death 5.4% ( 72/1329) 4.5% (50/ 1123) 5. 0% (57/ 1133) 2. 5% (57/2284) 5.1% ( 7/136) 6. 1% (6/98) 2.3% (5/ 217) 0.9% (2/219) 1.8% (1/ 56)
Q wav e MI 0.4% ( 5/1329) 1. 3% (15/ 1123) 0.8% (9/1133) 0.9% ( 20/2284) 0. 0% (0/136) 0.0% ( 0/98) 0.9% (2/217) 0.9% ( 2/219) 1. 8% (1/56)
Non-Q Wave MI 2.9% (38/1329) 4.6% ( 52/1123) 4. 9% (56/1133) 3. 0% (69/ 2284) 6.6% (9/136) 4. 1% (4/98) 5.1% ( 11/217) 3. 2% (7/219) 3.6% (2/56)
1.3% ( 18/1402) 3.8% (43/ 1140) 4. 7% (54/ 1152) 2. 6% (61/2349) 4.3% ( 6/139) 2. 0% (2/ 100) 3.6% ( 8/223) 1.7% (4/ 230) 1. 8% (1/ 56)
0.0% ( 0/1402) 0.0% (0/1140) 0.2% ( 2/1152) 0.0% (1/ 2349) 0.0% (0/ 139) 0.0% ( 0/100) 0. 0% (0/ 223) 0.0% (0/230) 0.0% ( 0/56)
1.1% ( 16/1402) 3.1% (35/ 1140)
0.1% ( 2/1390)
1.2% ( 16/1390)
0.1% ( 2/1390) 1. 6% (18/ 1132) 0.7% (8/1142) 0.9% ( 20/2337) 0. 0% (0/139) 0. 0% (0/ 100) 0. 9% (2/222) 0. 9% (2/ 226) 1.8% (1/56)
RESOLUTE INTEGRITY US
Resolute Integrity
(PEG)
(N= 230)
RESOLUTE
INTEGRITY US (XL
Sub-study)
N=56)
1
0
Table 8-1: Principal Adverse Events from Post-Procedure Through Latest Available Follow-up
(
38 mm Length Sub-
RESOLUTE US
Cardiac Death or T VMI
Clinically Driv en TVR
TLR
Non-TL TVR
ARC Def/Prob ST
1
Resol ute
(N = 1402)
6.7% ( 89/1329) 11. 5% (129/1123) 10.6% (120/ 1133) 7. 0% (161/2284) 8.1% (11/ 136) 5. 1% (5/98) 8.8% ( 19/217) 5.9% (13/ 219) 7.1% (4/ 56)
12.5% ( 166/1329) 11.4% (128/ 1123) 10. 9% (123/1133) 7. 4% (168/2284) 5.1% (7/136) 5. 1% (5/98) 9.7% ( 21/217) 8.2% (18/ 219) 7.1% (4/56)
6.5% ( 86/1329) 7.8% (88/ 1123) 7. 1% (81/ 1133) 5.7% (130/2284) 2.9% ( 4/136) 1.0% (1/98) 6. 0% (13/217) 5. 0% (11/ 219) 5.4% (3/56)
8.1% ( 107/1329) 6.1% (68/ 1123) 6. 1% (69/ 1133) 2. 6% (59/2284) 2.2% ( 3/136) 4. 1% (4/98) 3. 7% (8/217) 4. 1% (9/219) 5.4% (3/56)
0.5% ( 7/1329) 2. 4% (27/ 1123) 1.7% ( 19/1133) 1. 1% (26/2284) 0. 0% (0/ 136) 0.0% (0/ 98) 1.4% ( 3/217) 1. 8% (4/219) 1. 8% (1/ 56)
RESOLUTE AC RESOLUTE Int RESOLUTE FIM RESOLUTE Japan
Resol ute
(N = 1140)
Xi ence V
(N = 1152)
Resol ute
(N = 2349)
Resol ute
(N = 139)
Resol ute
(N = 100)
study
R-US N = 114
R-Asia N = 109
Resol ute
(N = 223)
RESOLUTE INTEGRITY US
Resolute Integrity
(PEG)
(N= 230)
Notes
N = The t otal number of subject s enrolled.
The numbers are % (Count/Number of Eligible Subjects).
Subjects are only counted once for each time period.
NA = Not applicable; variable and/or time point not calculated
In-hospital is defined as hospitalization less than or equal to the discharge date
12-month timeframe includes follow-up window (360 days ± 30 days ).
24-month timeframe includes follow-up window (720 days ±30 days).
36-month timeframe includes follow-up window (1080 days ±30 days).
60-month timeframe includes follow-up window (1800 days ±30 days).
1
Primary Enrollment Group consisted of 1402 subjects, including 1242 subjects in the 2.25 - 3.5 mm Main Study, 100 subjec ts in the 2.25 - 3.5 m m
Angio/IVUS Sub-study and 60 subjects in the 4.0 mm Sub-study. The Primary Enrollment Group does not include the 38 mm Length Sub-study
2
Target Lesion Failure (TLF) is defined as any Cardiac Death, Clinically Driven Target Lesion Revascularization by PCI or CABG or Target Vessel MI.
3
Target Vessel Failure (TVF) is defined as any Cardiac Death, Clinically Driven Target Vessel Revascularization by PCI or CABG or Target Vessel MI.
4
Major adverse cardiac events (MACE) is defined as composite of death, MI (Q wave and non-Q wave), emergent bypass surgery, or clinically driven
target lesion revascularization (repeat PTCA or CABG).
5
TVMI is composed of both Q wave and non-Q wave MI which are not clearly attributable to a non-target vessel.
Q wave MI defined when any occurrence of chest pain or other acute symptoms c onsistent with my ocardial ischem ia and new pathological Q waves in
two or more contiguous ECG leads as determined by an ECG core laboratory or independent review of the CEC, in the absence of timely cardiac
enzyme data, or new pathologic Q waves in two or more contiguous ECG leads as determined by an ECG core laboratory or independent review of the
CEC and elevation of cardiac enzymes. In the absence of ECG data, the CEC may adjudicate Q wave MI based on the clinical scenario and appropriate
cardiac enzyme data.
Non-Q Wave MI is defined as elevated CK ; the upper laboratory normal with the presence of elevated CK-MB (any amount above the institution’s
upper limit of normal) in the absence of new pathological Q waves.
[Note: Periprocedural MIs (events <48 hours post-PC I) that did not fulf ill the criteria f or Q-wav e MI are included in N on-Q Wav e MI cat egory.
Periprocedural MIs did not require clinical symptoms or ECG evidence of myocardial ischemia, and in the absence of CK measurements, were based on
an elevated CKMB >3 X the upper laboratory normal, an elevated troponin >3 X the upper laboratory normal, or CEC adjudication of the clinical
scenario.]
6
Cardiac death/TVMI is defined as Cardiac Death or Myocardial Infarction not clearly att ributable to a non-target vessel.
7
Target Vessel Revascularization (TVR) is defined as any clinically-driven repeat intervention of the target vessel by PCI or CABG.
8
Target Lesion Revascularization (TLR) is defined as a clinically-driven repeat intervention of the target lesion by PCI or CABG
9
See Table 9-4 for the definition of the ARC defined Stent Thrombosis.
RESOLUTE
INTEGRITY US (XL
Sub-study)
N=56)
2
8.2 Potential Adverse Events
8.2.1 Potential Adverse Events Related to Zotarolimus
Patients’ exposure to zotarolimus is directly related to the total amount of stent length implanted. The
actual sid e effects/complications that may be associated with the use of zotarolimus are not fully known.
The adverse events that have been associated with the intravenous injection of zotarolimus in humans
include but are not limited to:
• Anemia
• Diarrhea
• Dry Skin
• Headache
• Hematuria
• Infection
• Injectio n site reaction
• Pain (abdominal, arthralgia, injection site)
• Rash
8.2.2 Potential Adverse Events Related to BioLinx polymer
Although the type of risks of the BioLinx polymer coating are expected to be no different than those of
other stent coatings, the potential for these risks are currently unknown as the coating has limited
previous use in humans. These risks may include but are not limited to the following:
• Allergic reaction
• Fo cal inflammation at the site of stent implantation
• Resteno sis of the stented artery
8.2.3 Potential Risks Associated with Percutaneous Coronary Diagnostic and Treatment Procedures
Other risks associated with using this device are those associated with percutaneous coronary
diagnostic (including angiography and IVUS) and treatment procedures. These risks (in alphabetical
order) may include but are not limited to the following:
• Abrupt vessel closure
• Access site pain, hematoma or hemorrhage
• Allerg ic reaction (to contrast, antiplatelet therapy, stent material, or drug and polymer
co ating)
• Aneurysm, pseudoaneurysm, or arteriovenous fistula (AVF)
• Arrhythmias, including ventricular fibrillation
• Balloon rupture
• Bleeding
• Cardiac tamponade
• Coronary artery occlusion, perforation, rupture, or dissection
• Coro nary artery spasm
• Death
• Embolism (air, tissue, d evice, or thrombus)
• Emergency surgery: peripheral vascular or coronary bypass
• Failure to deliver the stent
• Hemorrhage requiring transfusion
• Hypotension / hypertension
• Inco mplete stent apposition
• Infection or fever
• Myocardial infarction (MI)
• Pericarditis
• Peripheral ischemia / peripheral nerve injury
• Renal Failure
21
2
• Resteno sis of the stented artery
• Shock / pulmonary edema
• Stable o r Unstable angina
• Stent deformation, collapse, or fracture
• Stent migration or embolization
• Stent misplacement
• Stroke / transient ischemic attack
• Thrombosis (acute, subacute or late)
9 CLINICAL STUDI ES
9.1 Results of the RESOLUTE US Trial
Primary Objective: To assess the safety and effectiveness of the Resolute Zotarolimus-Eluting
Coronary Stent System (Resolute stent) for the treatment of de novo lesions in native coronary arteries
with a ref erence vessel diameter (RVD) of 2.25 to 4.2 mm.
Design: This is a prospective, multi-center, non-randomized controlled trial that evaluated the safety
and ef fectiveness of the Resolute stent for treatment of de novo lesions in native coronary artery(ies)
with ref erence vessel diameters (RVD) ranging from 2.25 to 4.2 mm. The study population included
sub jects from 116 sites in the United States with clinical evidence of ischemic heart disease due to
stenotic lesions with either one target lesion or two target lesions located in separate arteries, RVD
between 2.25 and 4.2 mm, lesions with stenosis but <100%, lesion length mm for the 38
mm Leng th Group), and TIMI f low 2.
The RESOLUTE US trial consists of the following:
• The 2.25 mm to 3.5 mm Main Study
• The 2.25 mm cohort analysis
• The 2.25 mm to 3.5 mm Angio/IVUS Sub-study
• The 4.0 mm stent Sub-study
• The 38 mm Length Group
3
Fig ure 9-1 provides a chart of the subject study designation of the primary enrollment group. The
primary enrollment group consists of the subjects in all of these studies and includes 1402 subjects.
Subject enrollment criteria common to all four studies listed above included: age >18 years old; clinical
evidence of ischemic heart disease, stable or unstable angina, silent ischemia, and/or a positive
f unctional study; and no evidence of an acute MI within 72 hours of the procedure.
Follow-up was completed at 30 days, 6, 9 and 12 months and will be performed at 18 months, 2, 3, 4
and 5 years. All subjects enrolled in the 2.25 mm – 3.5 mm Angio/IVUS Sub-study were consented to
angiographic and IVUS follow-up at 8 months post-procedure. All subjects enrolled in the 4.0 mm Substudy were consented to angiographic follow-up at 8 months post-procedure. Following the index
procedure, subjects were to be treated with aspirin indefinitely and clopidogrel/ticlopidine for a minimum
of 6 months and up to 12 months in subjects who were not at a hig h risk of bleeding.
The 12-mo nth and 5-year follow-up rates for the primary enrollment group were 97.3% (1364/1402) and
92.2% (1293/1402) respectively.
Strengths of this analysis include the collection and presentation of both short and long term outcomes
demonstrating safety and effectiveness in the intended population. A limitation was that the patient and
lesion characteristics excluded many complex subjects.
3
The 38 mm data was analyzed separately from the R-US Primary Enrollment Group.
2
3
Figure 9-1: Study Designation of RESOLUTE US Clinical Trial
2
4
2.5 mm – 3.5 mm Subset of the Main Study
(
Demographics and clinical characteristics: There were 1112 sub jects (1001 single lesion subjects
and 111 dual vessel subjects). The mean ag e of all subjects was 63.9 years with 69.2% (770/1112)
being males, 20.3% (222/1095) had a prior history of MI, 32.2% (358/1112) had a prior history of PCI,
and 7.6% (85/1112) had previous CABG surgery. 33.6% (374/1112) were diabetics, with 9.5%
(106/1112) being insulin dependent diabetics. Past medical history of subjects indicated 87.9%
(978/1112) had hyperlipidemia, 83.5% (928/1112) had hypertension, and 21.6% (240/1112) were
current smokers. The mean RVD by QCA was 2.63 ± 0.42 mm, the lesion length was 13.06 ± 5.84 mm,
and the average percentage diameter stenosis was 70.68 ± 11.56%. 75.8% of lesions (921/1215) were
characterized as ACC/AHA type B2/C.
Primary Endpoint: The primary endpoint in the 2.5 mm - 3.5 mm Subset of the Main Study was Target
Lesion Failure (TLF) at 12 months post-procedure. TLF was defined as the Cardiac Death, Target
Vessel Myocardial Infarction (MI), or clinically-driven Target Lesion Revascularization (TLR).
Control Group and Statistical Analysis Plan: The primary analysis was a non-inferiority comparison
of the 12-month TLF rate between the single lesion subset of the Resolute stent arm and a historical
co ntrol group consisting of single lesion subjects treated with Endeavor stents who were part of the
clinical follow-up cohort with diameters between 2.5 mm and 3.5 mm pooled from the following studies:
ENDEAVOR II, ENDEAVOR II Continued Access, ENDEAVOR IV, and ENDEAVOR US PK.
Results: The Resolute stent single lesion cohort of the 2.5 mm – 3.5 mm subset of the Main Study met
the p rimary 12-month TLF non-inferiority endpoint with the Resolute stent demonstrating a rate of 3.6%
(36/994) in comparison to the Endeavor stent historical control rate of 6.5% (70/1076), P
<0.001.
inferiority
These analyses are based on the intent-to-treat population. The results are presented in the following
tables:
• Table 9-1: RESOLUTE US 2.5 mm - 3.5 mm Subset of the Main Study - Primary Endpoint Analysis)
• Table 9-2: RESOLUTE US 2.5 mm - 3.5 mm Subset of the Main Study - Principal Safety and
Ef fectiveness - Single Lesion Outcome versus Historical Control (Endeavor)
• Table 9-3: RESOLUTE US 2.5 mm - 3.5 mm Subset of the Main Study - Principal Safety and
Ef fectiveness - Combined Single Lesion and Dual Lesion - Treated Subjects
• Table 9-4: RESOLUTE US 2.5 mm - 3.5 mm Subset of the Main Study - ARC Defined
Definite/Probable Stent Thrombosis Through 60 Months
• Table 9-5: RESOLUTE US 2.5 mm - 3.5 mm Subset of the Main Study Clinical Results – Single
versus Dual Lesion Subjects
Table 9-1: RESOLUTE US 2.5 mm - 3.5 mm Subset of the Main Study - Primary Endpoint
Analysis
2.5 mm - 3.5 mm Subset of the Main
Study
12-month TLF- Single Lesion Subjects
Notes
N = The t otal number of subject s enrolled.
TLF = Target lesion failure
Subjects are only counted once for each time period.
The numbers are % (Count/Number of Eligible Subjects) or least squares mean ± standard error.
The primary endpoint analysis for the 2.5 mm – 3.5 mm subset of the Main Study only includes subjects with a single lesion.
12-month timeframe includes follow-up window (360 days ± 30 days ).
1
The CI and P-values are adjusted to propensity score, based on lesion length, baseline RVD, age, sex, diabetes, history of MI and w ors t
Canadian Cardiovascular Society Angina Class as the independent variables.
2
One sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 3.3%, to be compared at a 0.05
significance level.
Resolute
(N = 1001)
3.6% (36/994) 6.5% (70/1076) -2.9% -1.4% <0.001
Historical Control
Endeavor
N = 1092)
Difference: Resolute
–Historical Control
Upper
One-sided
95% CI1
non-
Non-inferiority
P-value
1,2
2
5
Table 9-2: RESOLUTE US 2.5 mm - 3.5 mm Subset of the Main
(
Study - Principal Safety and Effectiveness - Single Lesion Outcome
versus Historical Control
Single Lesion 2.5 mm - 3.5
Outcomes at 12 Months
COMPOSITE SAFETY AND EFFECTIVENESS
TLF 3.6% (36/994) 6.5% (70/1076)
TVF 5.0% (50/994) 8.3% (89/1076)
MACE 4.3% (43/994) 7.0% (75/1076)
EFFECTIVENESS
Clinically Driven TVR 3.7% (37/994) 6.0% (65/1076)
TLR 2.1% (21/994) 4.0% (43/1076)
TLR, PCI 1.8% (18/994) 3.7% (40/1076)
TLR, CABG 0.3% (3/994) 0.5% (5/1076)
Non-TL TVR 1.8% (18/994) 2.5% (27/1076)
Non-TL TVR, PCI 1.5% (15/994) 2.1% (23/1076)
Non-TL TVR, CABG 0.3% (3/994) 0.5% (5/1076)
SAFETY
Total Death 1.0% (10/994) 1.3% (14/1076)
Cardiac Death 0.5% (5/994) 0.8% (9/1076)
Non-Cardiac Death 0.5% (5/994) 0.5% (5/1076)
Cardiac Death or TVMI 1.7% (17/994) 3.2% (34/1076)
TVMI 1.2% (12/994) 2.4% (26/1076)
Q wave MI 0.2% (2/994) 0.3% (3/1076)
Non-Q wave MI 1.0% (10/994) 2.1% (23/1076)
Stent Thrombosis
ARC defined
Definite/Probable 0.0% (0/994) 0.7% (7/1076)
Definite 0.0% (0/994) 0.5% (5/1076)
Probable 0.0% (0/994) 0.2% (2/1076)
ACUTE SUCCESS
Procedure Success 98.7% (982/995) 97.6% (1060/1086)
Notes
N = The t otal number of subject s enrolled.
Numbers are % (Count/Number of Eligible Subjects).
Subjects are only counted once for each time period.
The definitions of the outcomes are presented as table notes to Table 8-1- Principal Adverse Events .
12-month timeframe includes follow-up window (360 days ± 30 days ).
Procedure success is defined as attainment of <50 % residual stenosis of the target lesion and no in-hospital MACE.
See Table 9-4 for the definition of the ARC defined Stent Thrombosis .
mm Subset of Main study
Endeavor)
(N = 1001 subjects)
Single Lesion
Historical Control (Endeavor)
(N = 1092 subjects)
2
6
Table 9-3: RESOLUTE US 2.5 mm - 3.5 mm Subset of the Main Study - Principal Safety and
Effectiveness - Combined Single Lesion and Dual Lesion – Treated Subjects Through 60
Months
2.5 mm – 3.5 mm subset of the Main Study (N = 1112) Outcomes at 12 Months Outcomes at 60 Month s
COMPOSITE SAFETY AND EFFECTIVENESS
TLF 3.8% (42/1105)
TVF 5.2% (58/1105)
MACE 4.6% (51/1105)
EFFECTIVENESS
Clinically Driven TVR
TLR
TLR, PCI
TLR, CABG
Non-TL TVR
Non-TL TVR, PCI
Non-TL TVR, CABG
3.9% (43/1105) 11.4% (120/1051)
2.3% (25/1105) 5.7% (60/1051)
2.0% (22/1105) 5.0% (53/1051)
0.3% (3/1105) 0.7% (7/1051)
1.9% (21/1105) 7.3% (77/1051)
1.5% (17/1105) 6.4% (67/1051)
0.4% (4/1105) 1.0% (10/1051)
SAFETY
Total Death
Cardiac Death
Non-Cardiac Death
1.0% (11/1105) 8.8% (92/1051)
0.5% (5/1105) 3.4% (36/1051)
0.5% (6/1105) 5.3% (56/1051)
Cardiac Death or TVMI 1.7% (19/1105)
TVMI
Q wave MI
Non-Q wave MI
Stent Thrombosis
ARC defined
1.3% (14/1105) 3.2% (34/1051)
0.2% (2/1105) 0.4% (4/1051)
1.1% (12/1105) 2.9% (30/1051)
Definite/Probable 0.0% (0/1105)
Definite 0.0% (0/1105)
Probable 0.0% (0/1105)
Notes
N = The t otal number of subject s enrolled.
Numbers are % (Count/Number of Eligible Subjects).
Subjects are only counted once for each time period.
The definitions of the outcomes are presented as table notes to Table 8-1- Principal Adverse Events .
12-month timeframe includes follow-up window (360 days ± 30 days ).
60-month timeframe includes follow-up window (1800 days ± 30 days ).
See Table 9-4 for the definition of the ARC defined Stent Thrombosis .
10.9% (115/1051)
16.1% (169/1051)
16.7% (175/1051)
6.0% (63/1051)
0.5% (5/1051)
0.3% (3/1051)
0.2% (2/1051)
2
7
g
(
Table 9-4: RESOLUTE US 2.5 mm - 3.5 mm Subset of the Main Study - ARC
Defined Definite/Probable Stent Thrombosis Throu
Stent Thrombosis
Acute (0 - 1 day)
Subacute (2 - 30 days)
Late (31 – 360 days)
Very Late (361 - 1800 days)
Notes
N = The t otal number of subject s enrolled.
Subjects are only counted once for each time period.
Numbers are % (Count/Number of Eligible Subjects).
60-month timeframe includes follow-up window (1800 days ±30 days).
To be included in the calculation of stent thrombosis (ST) rate for a given interval, a patient either had to have
a stent thrombosis during the interval (e.g. 31-360 days inclusive) or had to be stent thrombosis-free during the
interval with last follow-up on or after the first day of the given interv al (e.g. 31 days ).
Academic Research Consortium (ARC) stent thrombosis is defined as follows:
1. Definite ST is considered to have occurred after intracoronary stenting by either angiographic or
pathologic confirmation of stent thrombosis.
2. Probable ST is considered to have occurred aft er intracoronary stent ing in the f ollowing cases :
Any unex plained death within the firs t 30 days f ollowing s tent implant ation. Irrespective of the time after
the index procedure, any MI which is related to documented acute ischemia in the territory of the
implanted stent without angiographic confirmation of ST and in the absenc e of any other obv ious cause.
2.5 mm - 3.5 mm subset of the Main Study
N = 1112)
0.5% (5/1051)
0.0% (0/1051)
0.0% (0/1051)
0.0% (0/1051)
0.5% (5/1051)
h 60 Months
2
Loading...